Combination therapy with an inhibitor of TGFβ type I receptor (TGFβR1) kinase, galunisertib, anti-GD2 antibody and ex vivo activated NK cells, has been used by Tran et al. (55) in a mouse model of neuroblastoma with positive results. This evidence concerns the gene TGFBR1 and neuroblastoma.